FDA Approves Plegridy as Intramuscular Injection for Relapsing MS

FDA Approves Plegridy as Intramuscular Injection for Relapsing MS

284834

FDA Approves Plegridy as Intramuscular Injection for Relapsing MS

The U.S. Food and Drug Administration (FDA) has approved an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat people with relapsing forms of multiple sclerosis (MS). This formulation, for injection directly into muscle, is what is typically used to deliver the flu shot. According to Biogen, Plegridy’s developer, treatment given via intramuscular injection is as effective as the subcutaneous (under-the-skin) injection formulation long in use, but lowers the likelihood of injection site reactions. This new formulation…

You must be logged in to read/download the full post.